JULY 2024LIFE SCIENCES REVIEW6The life sciences field is experiencing a wave of innovations driven by powerful new tools. Key among these include CRISPR/Cas9 gene editing and personalized cell therapy, which are revamping the treatment of diseases. These advancements bring hope to patients with conditions such as sickle cell disease and advanced melanoma. Casgevy marks a milestone in medicine by using CRISPR/Cas9, a breakthrough gene-editing tool, to treat sickle cell disease in patients 12 and older prone to vaso-occlusive crises. The therapy modifies a patient's blood stem cells to produce more fetal hemoglobin, preventing sickling of red blood cells and improving oxygen transport. Another achievement comes with FDA approval of Amtagvi cell therapy, a pivotal advance in cancer care, targeting advanced melanoma with personalized immunotherapy. The treatment extracts and amplifies tumor-infiltrating lymphocytes (TILs) from a patient's tumor, enhancing their ability to combat cancer cells when reintroduced into the body, representing a significant leap in cancer treatment. Driven by these innovative therapies, the cell and gene therapy manufacturing market is set to soar to $106.03 billion by 2033, driven by a 26.7 percent CAGR. This growth underscores the rising demand and transformative impact of these therapies. This edition of the Life Sciences Review APAC offers insights into the latest trends in cell and gene therapy and how companies are aligning with these trends. Stay informed as industry leaders share their experiences and strategies for navigating the evolving landscape of cell and gene therapy standards and the growing demand for more user-friendly practices. The magazine features a thought-provoking article from Rachel Legmann, Senior Director of Technology, Gene Therapy at Repligen. In the article, he explains how advanced manufacturing platforms are crucial for enhancing viral vector yield and overcoming scalability challenges in gene therapy, ensuring efficient and reliable production of virus-based therapeutics. In this edition of Life Sciences Review APAC, we also feature Top Cell and Gene Therapy Companies in APAC 2024, we hope you find the right partner to meet your organization's needs. Let us know your thoughts! EDITORIALBreakthroughs in CRISPR and Personalized Cancer Treatment Copyright © 2024 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsJuly - 15 - 2024, Vol 05, Issue - 19 ( ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >